Published in Clin Pharmacol Ther on October 01, 1999
Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A (2000) 5.89
Use of herbal products and potential interactions in patients with cardiovascular diseases. J Am Coll Cardiol (2010) 3.77
Comparison of St John's wort and imipramine for treating depression: randomised controlled trial. BMJ (2000) 2.71
Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol (2001) 1.85
St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol (2002) 1.45
The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr Alzheimer Res (2004) 1.42
St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol (2002) 1.18
Interaction of St John's wort with conventional drugs: systematic review of clinical trials. BMJ (2004) 1.17
Dietary effects on drug metabolism and transport. Clin Pharmacokinet (2003) 1.11
Hyperforin in St. John's wort drug interactions. Eur J Clin Pharmacol (2006) 1.10
Overcoming drug resistance by regulating nuclear receptors. Adv Drug Deliv Rev (2010) 1.10
Children and natural health products: What a clinician should know. Paediatr Child Health (2005) 1.09
Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. Br J Clin Pharmacol (2003) 1.09
Sucralose, a synthetic organochlorine sweetener: overview of biological issues. J Toxicol Environ Health B Crit Rev (2013) 1.06
The ethics of dietary supplements and natural health products in pharmacy practice: a systematic documentary analysis. Int J Pharm Pract (2009) 1.06
Complementary and alternative medicine for children: does it work? Arch Dis Child (2001) 1.06
Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations. AAPS J (2009) 1.01
Herbal product-drug interactions mediated by induction. Br J Clin Pharmacol (2006) 1.00
The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials. Br J Clin Pharmacol (2006) 0.98
Methods to evaluate biliary excretion of drugs in humans: an updated review. Mol Pharm (2006) 0.98
Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol (2003) 0.97
Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception. Br J Clin Pharmacol (2003) 0.93
Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements. Br J Clin Pharmacol (2006) 0.92
Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos (2005) 0.91
Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res (2008) 0.89
Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol (2001) 0.89
Toxicity Profile of the Aqueous Ethanol Root Extract of Corrigiola telephiifolia Pourr. (Caryophyllaceae) in Rodents. Evid Based Complement Alternat Med (2010) 0.89
Application of Caco-2 cell line in herb-drug interaction studies: current approaches and challenges. J Pharm Pharm Sci (2014) 0.87
Effect of short term and chronic administration of Sutherlandia frutescens on pharmacokinetics of nevirapine in rats. Int J Pharm (2011) 0.87
The effect of Crataegus oxycantha Special Extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure. Eur J Heart Fail (2008) 0.86
Evaluation of knowledge base of hospital pharmacists and physicians on herbal medicines in Southwestern Nigeria. Pharm Pract (Granada) (2008) 0.85
Evaluating Term Coverage of Herbal and Dietary Supplements in Electronic Health Records. AMIA Annu Symp Proc (2015) 0.84
Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos (2006) 0.83
[Pharmacokinetic drug interactions by herbal drugs: Critical evaluation and clinical relevance]. Wien Med Wochenschr (2010) 0.82
Identifying and reducing complications of outpatient medications. J Gen Intern Med (2000) 0.81
Ophiopogon japonicus strains from different cultivation regions exhibit markedly different properties on cytotoxicity, pregnane X receptor activation and cytochrome P450 3A4 induction. Biomed Rep (2015) 0.80
St John's wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive. Eur J Clin Pharmacol (2008) 0.79
Exposure of LS-180 cells to drugs of diverse physicochemical and therapeutic properties up-regulates P-glycoprotein expression and activity. J Pharm Pharm Sci (2011) 0.79
St. John's Wort enhances the synaptic activity of the nucleus of the solitary tract. Nutrition (2014) 0.79
Pharmacokinetic Interactions between Drugs and Botanical Dietary Supplements. Drug Metab Dispos (2015) 0.76
Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers. Eur J Clin Pharmacol (2004) 0.76
Drug-phytochemical interactions. Inflammopharmacology (2003) 0.75
Drug safety: The concept, inception and its importance in patients' health. Saudi Pharm J (2014) 0.75
[Not Available]. Paediatr Child Health (2005) 0.75
Which medications used in paediatric practice have demonstrated natural health product-drug interactions?: Part A: Evidence-based answer and summary. Paediatr Child Health (2006) 0.75
Herb-drug interaction: The importance of communicating with primary care physicians. Australas Med J (2015) 0.75
Complementary and alternative medicine for children: does it work? West J Med (2001) 0.75
Therapeutic Risk and Benefits of Concomitantly Using Herbal Medicines and Conventional Medicines: From the Perspectives of Evidence Based on Randomized Controlled Trials and Clinical Risk Management. Evid Based Complement Alternat Med (2017) 0.75
Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A (2000) 5.89
Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science (1998) 5.05
Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci U S A (1996) 4.69
An activating immunoreceptor complex formed by NKG2D and DAP10. Science (1999) 4.56
Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A (1999) 4.40
Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet (1997) 3.08
Protein kinase C phosphorylates the inhibitory guanine-nucleotide-binding regulatory component and apparently suppresses its function in hormonal inhibition of adenylate cyclase. Eur J Biochem (1985) 3.04
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry (2004) 2.98
Primary gastric B-cell lymphoma: results of a prospective multicenter study. The German-Austrian Gastrointestinal Lymphoma Study Group. Gastroenterology (2000) 2.65
Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther (2001) 2.62
Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol (1999) 2.57
Hazards of indiscriminate screening for sickling. N Engl J Med (1971) 2.38
The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics (2001) 2.21
The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther (2009) 2.19
The risks of blood transfusion: the relative influence of acquired immunodeficiency syndrome and non-A, non-B hepatitis. Am J Med (1992) 2.12
Higher blood flow and circulating NO products offset high-altitude hypoxia among Tibetans. Proc Natl Acad Sci U S A (2007) 2.07
In vivo and in vitro complex formation of prostate specific antigen with alpha 1-anti-chymotrypsin. Prostate (1995) 2.07
Autoradiographic study of mannan incorporation into the growing cell walls of Saccharomyces cerevisiae. J Bacteriol (1974) 1.94
Nomenclature for human CYP2D6 alleles. Pharmacogenetics (1996) 1.91
A new rapid slide test for infectious mononucleosis. JAMA (1965) 1.82
Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus. J Neurol Neurosurg Psychiatry (2007) 1.80
Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet (1995) 1.79
Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol (1999) 1.76
A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res (1996) 1.74
The surrogate light chain in B-cell development. Immunol Today (1993) 1.64
Dense growth of aerobic bacteria in a bench-scale fermentor. Biotechnol Bioeng (1976) 1.62
Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Clin Cancer Res (2001) 1.62
Reduced nicotinamide adenine dinucleotide phosphate (NADPH)-dependent formation and breakdown of hydrogen peroxide during mixed function oxidation reactions in liver microsomes. Arch Biochem Biophys (1975) 1.60
CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand (2001) 1.59
Analysis of the SlyA-controlled expression, subcellular localization and pore-forming activity of a 34 kDa haemolysin (ClyA) from Escherichia coli K-12. Mol Microbiol (1999) 1.55
Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J (2006) 1.53
Characterization of the glutathione S-transferase GSTT1 deletion: discrimination of all genotypes by polymerase chain reaction indicates a trimodular genotype-phenotype correlation. Pharmacogenetics (2000) 1.52
Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry (2000) 1.52
Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer (2007) 1.52
Endoscopic evaluation of exercise-induced pulmonary hemorrhage and chronic obstructive pulmonary disease in association with poor performance in racing Standardbreds. J Am Vet Med Assoc (1990) 1.51
Role of Kozak sequence polymorphism of platelet glycoprotein Ibalpha as a risk factor for coronary artery disease and catheter interventions. J Am Coll Cardiol (2001) 1.51
Secretion of cell-wall glycoproteins by yeast protoplasts. Effect of 2-deoxy-D-glucose and cycloheximide. Biochem J (1970) 1.48
Lack of DNA synthesis among CD34+ cells in cord blood and in cytokine-mobilized blood. Br J Haematol (1996) 1.48
Reduced procedural risk for coronary catheter interventions in carriers of the coagulation factor VII-Gln353 gene. J Am Coll Cardiol (2000) 1.45
SlyA, a regulatory protein from Salmonella typhimurium, induces a haemolytic and pore-forming protein in Escherichia coli. Mol Gen Genet (1995) 1.45
Arterial hypoxemia following the administration of sublingual nitroglycerin. Am Heart J (1978) 1.44
Effect of surgical repair on the neurologic function in infants with lipomeningocele. Pediatr Neurosurg (1993) 1.40
Modulation of adenylate cyclase of human platelets by phorbol ester. Impairment of the hormone-sensitive inhibitory pathway. Eur J Biochem (1985) 1.39
Immunosuppressive properties of cyclosporin metabolites. Lancet (1989) 1.39
Hydrogen peroxide in hepatic microsomes. Methods Enzymol (1978) 1.38
Demonstration of cGMP-dependent protein kinase and cGMP-dependent phosphorylation in cell-free extracts of platelets. Eur J Biochem (1986) 1.31
Extracellular beta-glucanases of the yeast, Saccharomyces cerevisiae. Biochim Biophys Acta (1973) 1.31
Genotype and phenotype of glutathione S-transferase class mu isoenzymes mu and psi in lung cancer patients and controls. Cancer Res (1993) 1.29
Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene. Proc Natl Acad Sci U S A (1989) 1.25
Metabolism of 2-deoxy-D glucose by Baker's yeast. IV. Incorporation of 2-deoxy-D-glucose into cell wall mannan. Biochim Biophys Acta (1972) 1.24
Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther (1999) 1.23
Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther (1992) 1.22
High mobility, low voltage operating C(60) based n-type organic field effect transistors. Synth Met (2011) 1.21
Xylan-degrading activity in yeasts: growth on xylose, xylan and hemicelluloses. Folia Microbiol (Praha) (1978) 1.20
Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. Pharmacogenomics J (2005) 1.19
Crystal structure of the MHC class I homolog MIC-A, a gammadelta T cell ligand. Immunity (1999) 1.19
A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: a case-controlled study. Lancet (1999) 1.18
Mechanism of 2-deoxy-D-glucose inhibition of cell-wall polysaccharide and glycoprotein biosyntheses in Saccharomyces cerevisiae. Eur J Biochem (1975) 1.18
Commissioning of a micro multi-leaf collimator and planning system for stereotactic radiosurgery. Radiother Oncol (1999) 1.18
T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28. Blood (1996) 1.17
Target size of calcium pump protein from skeletal muscle sarcoplasmic reticulum. J Biol Chem (1984) 1.16
Characterization of the junctional face membrane from terminal cisternae of sarcoplasmic reticulum. J Cell Biol (1986) 1.16
Effect of 2-deoxyglucose on cell wall formation in Saccharomyces cerevisiae and its relation to cell growth inhibition. J Bacteriol (1971) 1.13
Maximal exponential growth rate and yield of E. coli obtainable in a bench-scale fermentor. Biotechnol Bioeng (1974) 1.13
A single origin of phenylketonuria in Yemenite Jews. Nature (1990) 1.11
The oxidation of fatty acids by a particulate fraction from desert-locust (Schistocerca gregaria) thorax tissues. Biochem J (1960) 1.10
In vivo CTL induction with point-substituted ovalbumin peptides: immunogenicity correlates with peptide-induced MHC class I stability. Vaccine (1995) 1.10
High CA repeat numbers in intron 13 of the endothelial nitric oxide synthase gene and increased risk of coronary artery disease. Pharmacogenetics (2000) 1.09
Arylamine N-acetyltransferase activity in man. Drug Metab Rev (1999) 1.09
Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia. J Exp Med (1996) 1.08
[The value of pharmacogenetic tests in antidepressive medication therapy]. Nervenarzt (2005) 1.07
Progressive liver calcifications in neonatal coxsackievirus infection. Pediatr Radiol (2000) 1.07
Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. Clin Pharmacol Ther (1994) 1.06
Crystal structure of the murine NK cell-activating receptor NKG2D at 1.95 A. Nat Immunol (2001) 1.06
RP1, a new member of the adenomatous polyposis coli-binding EB1-like gene family, is differentially expressed in activated T cells. J Immunol (1997) 1.06
Evaluation of in vivo parameters of drug metabolizing enzyme activity in man after administration of clemastine, phenobarbital or placebo. Eur J Clin Pharmacol (1975) 1.06
The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J (2001) 1.05